Screening for prostate cancer: Have you had your cholesterol measured?

BJU International

Volumn 92, Issue 3, 2003, Pages 191-199

  Boyle, P ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Outcome; Prostate cancer; PSA testing; Screening

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; CHOLESTEROL; ESTROGEN; GONADORELIN AGONIST; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CYSTITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENTERITIS; FECES INCONTINENCE; HEALTH CARE COST; HEALTH SURVEY; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; ORCHIECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTITIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; SHORT SURVEY; URINE INCONTINENCE;

AGE DISTRIBUTION; CHOLESTEROL; FORECASTING; HEALTH PROMOTION; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 0042635473     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04306.x     Document Type: Short Survey

References (42)

1. Jacobsen SJ, Bergstralh EJ, Katusic SK et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998; 52: 173-9
2. Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 1998; 5: 99-103
3. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337: 1526-9
4. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-23
5. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
6. Giovannucci E, Kantoff P, Spiegelman D et al. The epidemic of prostate cancer and the medical literature: a causal association? Prostate Cancer Prostatic Dis 1998; 1: 148-83
7. Parkes C, Wald NJ, Murphy P et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995; 311: 1340-3
8. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: follow-up study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 2189-91
9. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002 http://seer.cancer.gov/csr/1973_1999
10. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788-9
11. Tarone R, Chu K, Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167-70
12. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol. Austria Urol 2001; 58: 417-24
13. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the 'PSA ERA'. Int J Cancer 2001; 92: 893-8
14. Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention. Eur Urol 1999; 35: 370-6
15. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997 and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161: 529-33
16. Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer - part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-24
17. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163: 503-10
18. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001; 23: 181-6
19. Chirpaz E, Colonna M, Menegoz F et al. Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer 2002; 97: 372-6
20. Skarsgard D, Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 2000; 11: 79-88
21. Coldman AJ, Phillips N, Pickles TA. Tends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003; 168: 31-5
22. Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia, trends in incidence and mortality from 1985 to 1996. Medical J Aust 1998; 169: 21-4
23. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ 2002; 166: 586-91
24. Lu-Yao G, Albertsen P, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 2002; 325: 740-5
25. Yao SL, Lu-Yao G. Population-based study of relationships between hospital Volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999; 91: 1980-6
26. Bishoff JT, Motley G, Optenberg SA et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol 1998; 160: 454-8
27. Hamilton AS, Stanford JL, Gilliland FD et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 2517-26
28. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. ERSPC Prostate cancer mortality reduction by screening, power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268-73
29. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-72
30. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death, first analysis of the 1998 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91
31. Zelen M. Are primary cancer prevention trials feasible? J Natl Cancer Inst 1988; 80: 1442-4
32. Harris R, Lohr KN. Screening for prostate cancer. An update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 917-29
33. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173-81
34. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-34
35. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-2
36. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991 to 1998. Urology 2002; 59: 251-5
37. McGregor SE, Bryant HE, Brant RF, Corbett PJ. Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men. Chronic Dis Can 2002; 23: 111-9
38. Smith DP, Armstrong BK. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 1998; 169: 17-20
39. Russo A, Autelitano M, Bellini A, Bisanti L. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen 2002; 9: 179-80
40. Paez A, Lujan M, Llanes L et al. PSA-use in a Spanish industrial area. Eur Urol 2002; 41: 162-6
41. Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 2002; 113: 663-7
42. Mettlin C. Impact of screening on prostate cancer rates and trends. Microsc Res Tech 2000; 51: 415-8